Bowen Acquisition Corp Receives NASDAQ Notification of Non-Compliance with Listing Rules
New York, NY, May 29, 2025 (GLOBE NEWSWIRE) — Bowen Acquisition Corp (NASDAQ: BOWN) ('BOWN'), a special purpose acquisition company, announced that on May 28, 2025, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ('NASDAQ') advising the Company that the Company does not comply with NASDAQ's Listing Rule 5250(c)(1) for continued listing because NASDAQ has not received the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 (the 'Form 10-Q'). NASDAQ has informed the Company that it has until July 28, 2025 to submit a plan to regain compliance with respect to this delinquent report. If NASDAQ approves the Company's plan, it has the discretion to grant the Company an extension of up to 180 calendar days from the due date of the Form 10-Q (or until November 17, 2025) to regain compliance.
The Company is working diligently to complete the Form 10-Q. If the Company is unable to file the Form 10-Q by July 28, 2025, it intends to file a plan to regain compliance with NASDAQ. This notification has no immediate effect on the listing of the Company's securities on NASDAQ. There can be no assurance, however, that the Company will be able to regain compliance with the listing requirements discussed above or otherwise satisfy the other NASDAQ listing criteria.
About Bowen Acquisition Corp
Bowen Acquisition Corp is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. As previously disclosed, Bowen has entered into a definitive agreement for a business combination with Shenzhen Qianzhi BioTechnology Co., Ltd.
Forward Looking Statements
This press release includes certain 'forward-looking' statements, as that term is defined under the federal securities laws. Actual results may differ from expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements generally are identified by the words or phrases such as 'aspire,' 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'will be,' 'will continue,' 'will likely result,' 'could,' 'should,' 'believe(s),' 'predicts,' 'potential,' 'continue,' 'future,' 'opportunity,' seek,' 'intend,' 'strategy,' or the negative version of those words or phrases or similar expressions are intended to identify such forward-looking statements. You should not place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date hereof, and, except as required by law, the Company assumes no obligation and does not intend to update any forward-looking statement to reflect events or circumstances after the date hereof.
For investor and media inquiries, please contact:
Jiangang LuoChief Executive Officer
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
17 minutes ago
- Business Upturn
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders
Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today announced that it has entered into a resolution agreement (the 'Resolution Agreement') with Goodwood Inc., Goodwood Fund and Puccetti Funds Management Inc. (collectively, 'Goodwood') to resolve matters relating to the upcoming annual and special meeting of COSCIENS' shareholders that had been scheduled to be held on June 26, 2025 (the '2025 Annual Meeting'). Pursuant to the Resolution Agreement, COSCIENS has today implemented a consensual reconstitution of its board of directors designed to best position COSCIENS to create value for all its shareholders. As a result of that reconstitution, COSCIENS' board of directors now consists of the following six directors: Anthony J. Giovinazzo, Ulrich Kosciessa, Ronald W. Miller, Peter H. Puccetti, Robert A. Seager and David Spear (the 'Reconstituted Board'). To facilitate the timely dissemination of COSCIENS' management information circular for the 2025 Annual Meeting, the meeting date has been postponed for several days and the 2025 Annual Meeting will now occur on June 30, 2025. At the 2025 Annual Meeting, COSCIENS will nominate for re-election as directors the six individuals who are now serving on the Reconstituted Board (and no other nominees). Goodwood has agreed that it will vote all of the 257,257 common shares of COSCIENS, or approximately 8.2% of COSCIENS' outstanding common shares, beneficially owned, or controlled or directed, directly or indirectly, by Goodwood in favour of the re-election of these six directors at the 2025 Annual Meeting. COSCIENS expects to disseminate its management information circular for the 2025 Annual Meeting within the next week. The Reconstituted Board is committed to ensuring that COSCIENS benefits from strong corporate governance and effective board oversight and doing what is in the best interests of COSCIENS and all of its shareholders. As part of that, the Reconstituted Board intends to actively review COSCIENS' prospects and opportunities, and to take the actions necessary to best position COSCIENS to create value for shareholders. Mr. Puccetti has been appointed as Chair of the Reconstituted Board. The Audit Committee now consists of Mr. Spear (Committee Chair), Mr. Kosciessa and Mr. Puccetti. The Human Resources, Nominating and Governance Committee now consists of Mr. Seager (Committee Chair), Mr. Miller and Mr. Giovinazzo. COSCIENS thanks each of its outgoing directors for their service to COSCIENS and acknowledges the contributions they have made to position COSCIENS for success. Details regarding each of the directors of COSCIENS now comprising the Reconstituted Board, each of whom will be nominated for re-election at the 2025 Annual Meeting, are set forth below: Anthony J. Giovinazzo Anthony Giovinazzo has over 45 years of executive experience and is an internationally recognized expert in intellectual property, drug development and commercialization, including numerous licensing agreements, with more than 25 years experience in Central Nervous System diseases. From 2009 until 2017, Mr. Giovinazzo served as the President and Chief Executive Officer of NASDAQ-listed Cynapsus Therapeutics Inc., a specialty pharmaceutical company that developed the first successful sublingual apomorphine thin film strip for Parkinson's disease. The drug was approved for commercialisation by the United States Food and Drug Administration in 2020. Mr. Giovinazzo was a co-inventor of the drug, built Cynapsus' leadership team, and was instrumental in its strategy including its over-subscribed IPO and NASDAQ listing. Mr. Giovinazzo became a director of Cynapsus in 2012. During Mr. Giovinazzo's tenure, Cynapsus attracted the top tier of institutional and venture capital funds in the United States. Mr. Giovinazzo led the negotiations with several pharmaceutical companies that resulted in the Cdn. $841 million all-cash acquisition of Cynapsus by Sunovion Pharmaceuticals (Dainippon Sumitomo Pharmaceuticals) in 2021 (at a 120% premium to Cynapsus' closing price on the day of announcement). From April 2006 to November 2009, Mr. Giovinazzo served as the Chief Executive Officer of Cervelo Pharmaceuticals Inc., a biopharmaceutical company. From 2002 to 2006, he served as Chief Executive Officer of Cita NeuroPharmaceuticals Inc., a biopharmaceutical company. Mr. Giovinazzo is currently a director of TSXV-listed Conavi Medical Inc., a commercial stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. He is also currently the Chair of the Board of TSXV-listed Xortx Therapeutics Inc., a Phase 3 kidney and NDA pending Gout disease company. In 2014, Mr. Giovinazzo was a Canadian finalist in Life Sciences for the E&Y Entrepreneur of the Year. In 2017, he was the recipient of the Finance Monthly Game Changers award as well as the inaugural recipient of the Bloom Burton Award, which honors the best of the best in Canadian Life Sciences as judged by a panel of US experts. Mr. Giovinazzo has completed the Leadership and Strategy in Pharmaceuticals and Biotech from Harvard Business School. Mr. Giovinazzo also holds a Masters of Business Administration from IMD, Geneva Switzerland, a Graduate Certificate Studies in Canadian Law from Osgoode Hall Law School at York University, and a Bachelor of Arts in Economics and Accounting from McMaster University. Ulrich Kosciessa Dr. Kosciessa currently serves as the Chief Executive Officer of Germany-based Photonamic GmbH & Co. KG and as the Chief Operating Officer of Tokyo-based SBI Pharmaceuticals Co. LTD. He has worked for 20 years for Medac GmbH, a global pharmaceutical company with operations in 70 countries where he served as a member of the Executive Management Board, as Managing Director of Medac International and as Chairman of the Board of Medac Pharma Inc., a U.S.-based subsidiary of Medac GmbH focused on specialty pharmaceuticals for autoimmune diseases and cancer. Throughout his career at Medac, Dr. Kosciessa has formed several subsidiaries and affiliates as well as established a network of global partners, growing the Company's international business more than 50% since 2005. In addition, since 2006 Dr. Kosciessa has also served as Chief Executive Officer of Photonamic, a subsidiary of Medac GmbH focused on research and development of photodynamic therapy and diagnostics. He has successfully developed two Photonamic products currently marketed in Europe, North America, South America, the Asian Pacific region and Australia. From 2006 to 2008, Dr. Kosciessa served as Chief Executive Officer at Immune Laboratory of Hannover, a research-based organization focused on autologous dendritic cell-based tumor vaccines. Prior to joining Medac GmbH, Dr. Kosciessa was a postdoctoral researcher at the neuroscience/neurodegenerative diseases division of Schering AG, a multinational pharmaceutical company. He received a in Biology and a Ph.D. in Molecular Biology from Georg-August University of Göttingen, Germany. Ronald W. Miller Ronnie Miller was President and CEO of Hoffmann-La Roche Limited (Roche Canada) for 22 years (until 2022). In this role, he was responsible for the growth and success of the Canadian Pharmaceuticals Division, particularly as it relates to Roche's mandate of developing and delivering innovative healthcare solutions for Canadians. Ronnie has more than 43 years of extensive and varied experience in the pharmaceutical industry. Born in Scotland, Mr. Miller completed his Bachelor of Science in Economics and Geography at the University of Glasgow, then moved to Leeds, England to accept a job as a pharmaceutical sales representative. Mr. Miller advanced through a series of successive sales and management positions across the industry to become the National Sales Manager for Roche in the United Kingdom in 1988 and continued to move globally as a Product Manager in Switzerland and Deputy Divisional Director of the Pharmaceutical Division in Japan. He moved back to Switzerland to head up a global product launch before returning to the UK as Pharmaceuticals Director. Mr. Miller was appointed President and CEO of Roche Pharmaceuticals in Canada in May 2000 and became a Canadian citizen in 2008. Mr. Miller was re-elected as Chairman of the Board of Directors of Innovative Medicines Canada (IMC), the national association representing Canada's research-based pharmaceutical companies, from 2019 to 2022. He served as Chairman of the IMC Board in 2007 and has since fulfilled two subsequent terms as Past Chair. Prior to this, Mr. Miller was the Chair of the IMC Prairies Core Team and sat as Co-Chair of the Health Research Foundation. He also served on several committees including the IMC Public Affairs, Stakeholder Relations, the British Columbia Sub-Committee, and was Chair of the Federal Affairs/FPT Relations Standing Committee. Peter H. Puccetti Peter Puccetti is the founder, Chairman and Chief Investment Officer of Goodwood Inc., a Canadian independent investment management firm that has provided institutional and high-net-worth clients with alternative investment strategies for over 28 years. Mr. Puccetti has managed the flagship Goodwood Fund since its inception, and has over 30 years of investment experience with a focus on special situations value investing. Mr. Puccetti has served on a number of public and private boards of directors. Mr. Puccetti and Goodwood Inc. have become well-known in Canada for leading a variety of activist campaigns to implement positive change and unlock shareholder value with the trust and support of many of Canada's top institutional investment organizations. Prior to founding Goodwood Inc., Mr. Puccetti was an analyst, investment banker and partner of Sprott Securities Limited. Mr. Puccetti holds a Bachelor of Arts in Economics from Dalhousie University. Mr. Puccetti is also a CFA Charterholder. Robert A. Seager Robert Seager is a leading special situations advisor and has been centrally involved in directing high profile shareholder disputes, proxy contests, M&A transactions, special committee mandates, internal and independent corporate investigations and complex restructurings. Mr. Seager is a trusted strategic advisor to institutional and other significant stakeholders, boards of directors and executive management teams with respect to corporate governance matters involving both public and private companies, including providing guidance through crisis situations and critical opportunities. Mr. Seager is a Partner of Voorheis & Co. LLP and Executive Vice President, Seacombe Partners Inc. In 2023, Mr. Seager was appointed to the Securities Advisory Committee of the Ontario Securities Commission (OSC). This committee, comprised of leading securities practitioners and other industry experts, plays a crucial role in advising the OSC and its staff on a variety of matters including policy initiatives and capital markets trends. Prior to joining Voorheis & Co. LLP in 2017, Mr. Seager practiced securities law at Blake, Cassels & Graydon LLP, and completed a secondment with the Office of M&A at the OSC. Mr. Seager received his J.D. from the Schulich School of Law at Dalhousie University with a specialization in corporate law, his International Business Law Certification from the Global Law Program at the Bader International Study Centre, and his Bachelor of Commerce from the Sauder School of Business at the University of British Columbia. Rob has also completed Levels 1 and II of the CFA Program. David Spear David Spear is an accomplished entrepreneur and executive with more than 35 years of experience in the healthcare industry, with a particular focus on the eyecare sector. Mr. Spear is currently the President and Chief Strategy Officer of Advancing Eyecare, a partnership of leaders in the eyecare instrumentation marketplace established to offer the best products and service solutions in the ophthalmic equipment industry. Mr. Spear previously served as a director of Innova Medical Ophthalmics, a supplier to the Canadian ophthalmic community that he co-founded in 1987. Mr. Spear also previously served as a director of Advancing Eyecare from 2017 to 2023. Throughout his career, Mr. Spear has played a pivotal role in launching and leading multiple ventures within the ophthalmic and medical device industries. His entrepreneurial journey includes co-founding and managing S4OPTIK LLC, Blue.S4 Precision Manufacturing, Innovative Excimer Solutions, and S4OPTIK S.A. de C.V. in Mexico. Mr. Spear holds a Bachelor of Commerce from the University of Windsor and a Bachelor of Science in Biology from Western University. A copy of the Resolution Agreement will be made available on COSCIENS' profile on SEDAR+ at in due course. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements. All statements contained in this filing that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the words 'intends,' 'expects,' and similar expressions are generally intended to identify forward-looking statements. These statements are based on current expectations of COSCIENS and Goodwood and currently available information. They are not guarantees of future performance, involve certain risks and uncertainties that are difficult to predict, and are based upon assumptions as to future events that may not prove to be accurate. Neither COSCIENS nor Goodwood assume any obligation to update any forward-looking statements contained in this press release, except as required by applicable law. For further information contact: Peter H. PuccettiChairman of the BoardCOSCIENS Biopharma Inc. Tel: 416-203-2722 Email: [email protected]
Business Upturn
17 minutes ago
- Business Upturn
LGI Homes Debuts New CompleteHome™ Plus Section at Star Valley in Tucson, AZ
TUCSON, Ariz., May 30, 2025 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) is proud to announce the grand opening of a brand-new section at Star Valley, a popular neighborhood southwest of Tucson, Arizona. This expansion introduces the CompleteHome™ Plus package by LGI Homes to the Tucson area for the first time. The new section at Star Valley offers 126 homesites and features four brand-new floor plans, starting in the $360s. With the addition of the CompleteHome Plus™ lineup, LGI Homes is now offering an even wider range of homes to meet the needs of Tucson buyers seeking affordability with high-end design and premier finishes. 'We are extremely excited to introduce our CompleteHome Plus™ product in the Tucson market for the first time,' stated Dallas Murphy, Vice President of Operations for Arizona. 'This new section allows us to introduce four brand-new floor plans with elevated features such as 9-foot ceilings, upgraded wood cabinetry, beautiful quartz countertops, and luxury flooring, as well as new modern exterior elevations. It's the perfect combination of value, style and quality our customers are looking for.' New Floor Plans Available at Star Valley: The Bisbee: Single-story charm with 3 bedrooms, 2 bathrooms, and an open-concept layout that maximizes every square foot. Single-story charm with 3 bedrooms, 2 bathrooms, and an open-concept layout that maximizes every square foot. The Payson: Spacious and stylish home with a large living area, chef-ready kitchen, and secluded master retreat. Spacious and stylish home with a large living area, chef-ready kitchen, and secluded master retreat. The Wellton : Beautiful two-story home featuring a flexible loft space, extra downstairs bedroom, and an expansive layout perfect for growing families. : Beautiful two-story home featuring a flexible loft space, extra downstairs bedroom, and an expansive layout perfect for growing families. The Somerton: Thoughtfully designed two-story home with an open floor plan, upstairs loft, and a spacious covered patio. Each home is thoughtfully designed with modern finishes and elevated details. The kitchen showcases 42' wood cabinetry with crown molding, quartz countertops, a Whirlpool® self-clean gas range, a side-by-side refrigerator with an automatic ice maker and water dispenser, a stainless-steel undermount sink, Moen® faucets, and more. Interior features include 9-foot ceilings, luxury vinyl plank flooring in the main living areas, 2' faux wood blinds on select windows, ceiling fans with light kits in the family room and primary bedroom, matte black hardware on faucets and door handles, undermount bathroom sinks, and tiled shower surrounds. Smart-home enhancements such as Honeywell programmable thermostats and Wi-Fi-enabled LiftMaster® garage door openers add modern convenience. Exterior highlights include professionally designed desert landscaping and garage doors with sleek window accents. Located within a premier master-planned community known for its outstanding amenities, residents at Star Valley enjoy access to two fenced dog parks, a basketball court, barbecue grills, ramadas, walking trails and more. Designed to support an active and family-friendly lifestyle, this neighborhood offers everything buyers are looking for in a new home. LGI Homes will open the new section on Saturday, May 31, 2025 at Star Valley, featuring exclusive one day only discounts and incentives. For more information or to schedule a tour of the community, contact the Star Valley team at (855) 253-9683 ext. 977 or visit About LGI Homes Headquartered in The Woodlands, Texas, LGI Homes, Inc. is a pioneer in the homebuilding industry, successfully applying an innovative and systematic approach to the design, construction and sale of homes across 36 markets in 21 states. As one of America's fastest growing companies, LGI Homes has closed over 75,000 homes since its founding in 2003 and has delivered profitable financial results every year. Nationally recognized for its quality construction and exceptional customer service, LGI Homes was named to Newsweek's list of the World's Most Trustworthy Companies. LGI Homes' commitment to excellence extends to its more than 1,000 employees, earning the Company numerous workplace awards at the local, state and national level, including the Top Workplaces USA 2025 Award. For more information about LGI Homes and its unique operating model focused on making the dream of homeownership a reality for families across the nation, please visit the Company's website at MEDIA CONTACT:Rachel Eaton (281) 362-8998 ext. 2560
Business Upturn
17 minutes ago
- Business Upturn
AIOZ Network Unveils AIOZ AI: A Decentralized AI Marketplace and Compute Network Powered by DePIN
Grand Anse, May 30, 2025 (GLOBE NEWSWIRE) — Grand Anse, Mahe Island – Grand Anse, Mahe Island, Seychelles – AIOZ Network announces the launch of AIOZ AI, the first decentralized AI model and dataset marketplace built entirely on DePIN. As the foundational layer of AIOZ's infrastructure, DePIN powers a global network for AI computes, storage, streaming, and IPFS pinning service, enabling AI to be developed and deployed in a decentralized environment with greater transparency, control, and ownership. With this release, developers, researchers, and enterprises can upload, purchase, store, and monetize AI models and datasets across a distributed environment. AIOZ AI processes tasks through DePIN Compute, giving contributors ownership, transparency, and control over how their AI assets are used. 'With AIOZ AI, we're introducing a new foundation for decentralized AI. Built on DePIN, this platform empowers developers to share, monetize, and eventually tokenize their AI assets, from models to datasets and applications,' said Erman Tjiputra, Founder & CEO of AIOZ Network. 'It's part of our broader vision to create a unified infrastructure where people can store, stream, and compute in a decentralized way, with ownership and value returning to the contributors of the network.' DePIN: The Foundation of a Decentralized AI Economy AIOZ AI is built on DePIN Compute, a decentralized infrastructure that transforms how AI models are processed, stored, and monetized. The platform empowers users to upload models and datasets, unlock potential rewards when their assets are used, and access a growing ecosystem of decentralized AI applications. AI inferencing and compute tasks are executed on AIOZ's DePIN . This decentralized infrastructure ensures secure, permissionless access to AI processing while giving contributors a share in the network's growth. The AIOZ AI marketplace introduces an initial collection of AI models, datasets, and compute resources, giving early adopters access to a growing decentralized AI ecosystem. AIOZ AI Roadmap and Ecosystem Vision The launch of AIOZ AI marks the first step in building a decentralized AI ecosystem powered by DePIN Compute. V1 introduces foundational marketplace features, user accounts, payments, and the ability to upload, purchase, and monetize AI models and datasets, with built-in community features like voting and discussions. V2 will expand developer functionality by enabling larger file support, Git-based uploads, and API access via SDKs in Python, Go, and V3 will integrate DePIN-based AI inferencing, allowing developers to unlock potential rewards from verified model usage and compute tasks. V4 will introduce decentralized training, enabling models to be DePIN-trained and showcased in real-world applications. AIOZ AI is part of a broader DePIN-powered infrastructure developed by AIOZ Network. Alongside AI compute, the ecosystem includes AIOZ Stream for decentralized video and audio delivery, AIOZ Storage for S3-compatible Web3 data storage, and AIOZ Pin, an IPFS-based layer securing immutable assets like NFTs. Together, these components form a unified foundation for AI compute, content streaming, and digital storage, enabling a people-powered internet and defining the future of decentralized infrastructure. Driving Adoption Through the AIOZ AI Challenge To support the launch of AIOZ AI and accelerate developer adoption, AIOZ Network is introducing the AIOZ AI Challenge, a recurring competition series designed to spotlight AI talent and grow the platform's model and dataset library. The first wave of challenges will roll out after the platform's public release and run throughout 2025, providing participants the opportunity to build, submit, and refine AI models based on a defined technical framework. Submissions will be evaluated on performance, utility, and innovation, with leading models incentivized with potential tokens rewards and highlighted in the marketplace for greater discoverability. A public leaderboard will highlight top contributors, who may also gain early access to advanced features, future SDK integrations, and participation in exclusive collaborations. Join the Future of AI with AIOZ Network: Power AIOZ AI by Running AIOZ DePIN AIOZ AI runs on a decentralized backbone of contributors. By contributing to the AIOZ DePIN, users help drive AI model training, tasks inferencing, data storage, and unlock the potential for token rewards. No matter the background — tech enthusiast, AI developer, or blockchain believer — one's contribution fuels a cutting-edge, community-powered AI ecosystem. Everything Intelligence. AIOZ AI. Be the future redefining how AI is built and delivered. Start the journey today at About AIOZ Network: Powering Web3 Infrastructure Through DePIN AIOZ Network is pioneering the future of decentralized infrastructure by advancing DePIN across AI compute, media delivery, and distributed storage. AIOZ Network enables AI processing, content streaming, and secure data storage through a globally distributed network of over 200,000 contributors. The AIOZ ecosystem includes AIOZ AI, a decentralized compute and AI asset marketplace; AIOZ Stream, a platform for live and on-demand video and audio content; AIOZ Storage, an S3-compatible decentralized storage solution; and AIOZ Pin, a distributed IPFS pinning layer designed to store immutable content such as NFTs and digital assets. ### For more information about AIOZ Network, contact the company here: AIOZ NetworkMonica Botez [email protected] Grand Anse, Mahe Island, Seychelles
